Physician profile
Ming He
NPI 1497911531
$1,506.92
in general payments reported to CMS, 2019-2025
24 companies · $638 in 2025
The $638 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $26.55 · 2021: $63.86 · 2022: $73.30 · 2023: $313 · 2024: $174 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,090 · Education: $34.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,090.02 |
| Education | $34.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $416.95 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Abbvie INC. | $175.44 | 2021-2025 | |
| Argenx US, INC. | $105.67 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $105.10 | 2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $101.27 | 2023-2025 | Ultomiris |
| Lilly USA, LLC | $71.66 | 2023-2024 | Emgality, Reyvow |
| Averitas Pharma INC. | $68.32 | 2025 | Qutenza |
| Grifols USA, LLC | $59.28 | 2025 | Gamunex-C |
| Janssen Biotech, INC. | $50.49 | 2025 | |
| Sk Life Science, INC. | $50.28 | 2022-2025 | |
| Celgene Corporation | $48.11 | 2023 | Zeposia |
| Biogen, INC. | $38.70 | 2021-2025 | Vumerity, Tysabri |
| Neurelis, INC. | $32.26 | 2023-2025 | Valtoco |
| Allergan, INC. | $28.23 | 2022 | |
| Aucta Pharmaceuticals, INC. | $19.40 | 2024-2025 | Motpoly Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $18.47 | 2025 | Hyqvia |
| Octapharma USA, INC. | $16.18 | 2025 | Panzyga |
| Csl Behring | $15.69 | 2025 | Hizentra |
| Azurity Pharmaceuticals, INC. | $15.03 | 2023 | Gliadel |
| Teva Pharmaceuticals USA, INC. | $14.85 | 2024 | Austedo Xr |
| Jazz Pharmaceuticals INC. | $14.03 | 2025 | |
| Vanda Pharmaceuticals INC. | $13.90 | 2025 | Ponvory |
| Genentech USA, INC. | $13.87 | 2024 | Ocrevus, Enspryng |
| Lundbeck LLC | $13.74 | 2024 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ming He listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.